カテゴリー： 世界, 医療/バイオ, LP Information

世界の膜性腎症治療市場予測 2023年-2029年

【英語タイトル】Global Membranous Nephropathy Treatment Market Growth 2023-2029

LP Informationが出版した調査資料（LP23DC11025）・商品コード：LP23DC11025
・発行会社（調査会社）：LP Information
・発行日：2023年11月
・ページ数：105
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥556,320見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥834,480見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,112,640見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界の膜性腎症治療市場」は、過去の販売実績から2022年の世界の膜性腎症治療の総販売量を検討し、2023年から2029年の予測される膜性腎症治療の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の膜性腎症治療の市場規模を掲載し、XXX百万米ドル規模の世界の膜性腎症治療市場の詳細な分析を提供します。本インサイトレポートは、世界の膜性腎症治療業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の膜性腎症治療市場における各社の独自のポジションをより深く理解するために、膜性腎症治療製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の膜性腎症治療市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。膜性腎症治療の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。膜性腎症治療の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。膜性腎症治療のヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

膜性腎症治療の世界主要メーカーとしては、Abbie. Inc.、 Astrazeneca Plc.、 F. Hoffman- La Roche Ltd.、 Fibrogen、 Allergan Plc.、 Amgen Inc、 Pfizer Inc.、 Novartis. AG.、 Apotex Inc.、 Teva Pharma Industries Ltd.などを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の膜性腎症治療市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査では膜性腎症治療市場をセグメンテーションし、種類別 (アルキル化剤、シクロホスファミド、クロランブシル、環状ペプチド、タクロリムス、ミコフェノール酸モフェチル、その他)、用途別 (病院薬局、小売薬局、オンライン薬局)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：アルキル化剤、シクロホスファミド、クロランブシル、環状ペプチド、タクロリムス、ミコフェノール酸モフェチル、その他

・用途別区分：病院薬局、小売薬局、オンライン薬局

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界の膜性腎症治療市場の10年間の市場状況・展望は？
・世界および地域別に見た膜性腎症治療市場成長の要因は何か？
・膜性腎症治療の市場機会はエンドマーケットの規模によってどのように変化するのか？
・膜性腎症治療のタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：膜性腎症治療の年間販売量2018-2029、地域別現状・将来分析
・膜性腎症治療の種類別セグメント：アルキル化剤、シクロホスファミド、クロランブシル、環状ペプチド、タクロリムス、ミコフェノール酸モフェチル、その他
・膜性腎症治療の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・膜性腎症治療の用途別セグメント：病院薬局、小売薬局、オンライン薬局
・膜性腎症治療の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の膜性腎症治療市場
・企業別のグローバル膜性腎症治療市場データ：2018-2023年の年間販売量、市場シェア
・企業別の膜性腎症治療の年間売上：2018-2023年の売上、市場シェア
・企業別の膜性腎症治療販売価格
・主要企業の膜性腎症治療生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

膜性腎症治療の地域別レビュー
・地域別の膜性腎症治療市場規模2018-2023：年間販売量、売上
・主要国別の膜性腎症治療市場規模2018-2023：年間販売量、売上
・南北アメリカの膜性腎症治療販売の成長
・アジア太平洋の膜性腎症治療販売の成長
・ヨーロッパの膜性腎症治療販売の成長
・中東・アフリカの膜性腎症治療販売の成長

南北アメリカ市場
・南北アメリカの国別の膜性腎症治療販売量、売上（2018-2023）
・南北アメリカの膜性腎症治療の種類別販売量
・南北アメリカの膜性腎症治療の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の膜性腎症治療販売量、売上（2018-2023）
・アジア太平洋の膜性腎症治療の種類別販売量
・アジア太平洋の膜性腎症治療の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の膜性腎症治療販売量、売上（2018-2023）
・ヨーロッパの膜性腎症治療の種類別販売量
・ヨーロッパの膜性腎症治療の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の膜性腎症治療販売量、売上（2018-2023）
・中東・アフリカの膜性腎症治療の種類別販売量
・中東・アフリカの膜性腎症治療の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・膜性腎症治療の製造コスト構造分析
・膜性腎症治療の製造プロセス分析
・膜性腎症治療の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・膜性腎症治療の主要なグローバル販売業者
・膜性腎症治療の主要なグローバル顧客

地域別の膜性腎症治療市場予測レビュー
・地域別の膜性腎症治療市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・膜性腎症治療の種類別市場規模予測
・膜性腎症治療の用途別市場規模予測

主要企業分析
Abbie. Inc.、 Astrazeneca Plc.、 F. Hoffman- La Roche Ltd.、 Fibrogen、 Allergan Plc.、 Amgen Inc、 Pfizer Inc.、 Novartis. AG.、 Apotex Inc.、 Teva Pharma Industries Ltd.
・企業情報
・膜性腎症治療製品
・膜性腎症治療販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

The global Membranous Nephropathy Treatment market size is projected to grow from US$ 176.1 million in 2022 to US$ 259.7 million in 2029; it is expected to grow at a CAGR of 5.7% from 2023 to 2029.
United States market for Membranous Nephropathy Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Membranous Nephropathy Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Membranous Nephropathy Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Membranous Nephropathy Treatment players cover Abbie. Inc., Astrazeneca Plc., F. Hoffman- La Roche Ltd., Fibrogen, Allergan Plc., Amgen Inc, Pfizer Inc., Novartis. AG. and Apotex Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Membranous nephropathy (MN), also known as membranous glomerulopathy, is one of the many glomerular diseases causing nephrotic syndrome. It is characterized by proteinuria, presenting with peripheral edema and frothy urine. The etiology can be primary or secondary.
LPI (LP Information)’ newest research report, the “Membranous Nephropathy Treatment Industry Forecast” looks at past sales and reviews total world Membranous Nephropathy Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Membranous Nephropathy Treatment sales for 2023 through 2029. With Membranous Nephropathy Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Membranous Nephropathy Treatment industry.
This Insight Report provides a comprehensive analysis of the global Membranous Nephropathy Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Membranous Nephropathy Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Membranous Nephropathy Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Membranous Nephropathy Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Membranous Nephropathy Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Membranous Nephropathy Treatment market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Alkylating Agents
Cyclophosphamide
Chlorambucil
Cyclic Peptides
Tacrolimus
MycophenolateMofetil
Others
Segmentation by application
Hospital pharmacy
Retail pharmacy
Online Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Abbie. Inc.
Astrazeneca Plc.
F. Hoffman- La Roche Ltd.
Fibrogen
Allergan Plc.
Amgen Inc
Pfizer Inc.
Novartis. AG.
Apotex Inc.
Teva Pharma Industries Ltd.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Membranous Nephropathy Treatment market?
What factors are driving Membranous Nephropathy Treatment market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Membranous Nephropathy Treatment market opportunities vary by end market size?
How does Membranous Nephropathy Treatment break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Membranous Nephropathy Treatment Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Membranous Nephropathy Treatment by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Membranous Nephropathy Treatment by Country/Region, 2018, 2022 & 2029
2.2 Membranous Nephropathy Treatment Segment by Type
2.2.1 Alkylating Agents
2.2.2 Cyclophosphamide
2.2.3 Chlorambucil
2.2.4 Cyclic Peptides
2.2.5 Tacrolimus
2.2.6 MycophenolateMofetil
2.2.7 Others
2.3 Membranous Nephropathy Treatment Sales by Type
2.3.1 Global Membranous Nephropathy Treatment Sales Market Share by Type (2018-2023)
2.3.2 Global Membranous Nephropathy Treatment Revenue and Market Share by Type (2018-2023)
2.3.3 Global Membranous Nephropathy Treatment Sale Price by Type (2018-2023)
2.4 Membranous Nephropathy Treatment Segment by Application
2.4.1 Hospital pharmacy
2.4.2 Retail pharmacy
2.4.3 Online Pharmacy
2.5 Membranous Nephropathy Treatment Sales by Application
2.5.1 Global Membranous Nephropathy Treatment Sale Market Share by Application (2018-2023)
2.5.2 Global Membranous Nephropathy Treatment Revenue and Market Share by Application (2018-2023)
2.5.3 Global Membranous Nephropathy Treatment Sale Price by Application (2018-2023)
3 Global Membranous Nephropathy Treatment by Company
3.1 Global Membranous Nephropathy Treatment Breakdown Data by Company
3.1.1 Global Membranous Nephropathy Treatment Annual Sales by Company (2018-2023)
3.1.2 Global Membranous Nephropathy Treatment Sales Market Share by Company (2018-2023)
3.2 Global Membranous Nephropathy Treatment Annual Revenue by Company (2018-2023)
3.2.1 Global Membranous Nephropathy Treatment Revenue by Company (2018-2023)
3.2.2 Global Membranous Nephropathy Treatment Revenue Market Share by Company (2018-2023)
3.3 Global Membranous Nephropathy Treatment Sale Price by Company
3.4 Key Manufacturers Membranous Nephropathy Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Membranous Nephropathy Treatment Product Location Distribution
3.4.2 Players Membranous Nephropathy Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Membranous Nephropathy Treatment by Geographic Region
4.1 World Historic Membranous Nephropathy Treatment Market Size by Geographic Region (2018-2023)
4.1.1 Global Membranous Nephropathy Treatment Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Membranous Nephropathy Treatment Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Membranous Nephropathy Treatment Market Size by Country/Region (2018-2023)
4.2.1 Global Membranous Nephropathy Treatment Annual Sales by Country/Region (2018-2023)
4.2.2 Global Membranous Nephropathy Treatment Annual Revenue by Country/Region (2018-2023)
4.3 Americas Membranous Nephropathy Treatment Sales Growth
4.4 APAC Membranous Nephropathy Treatment Sales Growth
4.5 Europe Membranous Nephropathy Treatment Sales Growth
4.6 Middle East & Africa Membranous Nephropathy Treatment Sales Growth
5 Americas
5.1 Americas Membranous Nephropathy Treatment Sales by Country
5.1.1 Americas Membranous Nephropathy Treatment Sales by Country (2018-2023)
5.1.2 Americas Membranous Nephropathy Treatment Revenue by Country (2018-2023)
5.2 Americas Membranous Nephropathy Treatment Sales by Type
5.3 Americas Membranous Nephropathy Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Membranous Nephropathy Treatment Sales by Region
6.1.1 APAC Membranous Nephropathy Treatment Sales by Region (2018-2023)
6.1.2 APAC Membranous Nephropathy Treatment Revenue by Region (2018-2023)
6.2 APAC Membranous Nephropathy Treatment Sales by Type
6.3 APAC Membranous Nephropathy Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Membranous Nephropathy Treatment by Country
7.1.1 Europe Membranous Nephropathy Treatment Sales by Country (2018-2023)
7.1.2 Europe Membranous Nephropathy Treatment Revenue by Country (2018-2023)
7.2 Europe Membranous Nephropathy Treatment Sales by Type
7.3 Europe Membranous Nephropathy Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Membranous Nephropathy Treatment by Country
8.1.1 Middle East & Africa Membranous Nephropathy Treatment Sales by Country (2018-2023)
8.1.2 Middle East & Africa Membranous Nephropathy Treatment Revenue by Country (2018-2023)
8.2 Middle East & Africa Membranous Nephropathy Treatment Sales by Type
8.3 Middle East & Africa Membranous Nephropathy Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Membranous Nephropathy Treatment
10.3 Manufacturing Process Analysis of Membranous Nephropathy Treatment
10.4 Industry Chain Structure of Membranous Nephropathy Treatment
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Membranous Nephropathy Treatment Distributors
11.3 Membranous Nephropathy Treatment Customer
12 World Forecast Review for Membranous Nephropathy Treatment by Geographic Region
12.1 Global Membranous Nephropathy Treatment Market Size Forecast by Region
12.1.1 Global Membranous Nephropathy Treatment Forecast by Region (2024-2029)
12.1.2 Global Membranous Nephropathy Treatment Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Membranous Nephropathy Treatment Forecast by Type
12.7 Global Membranous Nephropathy Treatment Forecast by Application
13 Key Players Analysis
13.1 Abbie. Inc.
13.1.1 Abbie. Inc. Company Information
13.1.2 Abbie. Inc. Membranous Nephropathy Treatment Product Portfolios and Specifications
13.1.3 Abbie. Inc. Membranous Nephropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Abbie. Inc. Main Business Overview
13.1.5 Abbie. Inc. Latest Developments
13.2 Astrazeneca Plc.
13.2.1 Astrazeneca Plc. Company Information
13.2.2 Astrazeneca Plc. Membranous Nephropathy Treatment Product Portfolios and Specifications
13.2.3 Astrazeneca Plc. Membranous Nephropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Astrazeneca Plc. Main Business Overview
13.2.5 Astrazeneca Plc. Latest Developments
13.3 F. Hoffman- La Roche Ltd.
13.3.1 F. Hoffman- La Roche Ltd. Company Information
13.3.2 F. Hoffman- La Roche Ltd. Membranous Nephropathy Treatment Product Portfolios and Specifications
13.3.3 F. Hoffman- La Roche Ltd. Membranous Nephropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 F. Hoffman- La Roche Ltd. Main Business Overview
13.3.5 F. Hoffman- La Roche Ltd. Latest Developments
13.4 Fibrogen
13.4.1 Fibrogen Company Information
13.4.2 Fibrogen Membranous Nephropathy Treatment Product Portfolios and Specifications
13.4.3 Fibrogen Membranous Nephropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Fibrogen Main Business Overview
13.4.5 Fibrogen Latest Developments
13.5 Allergan Plc.
13.5.1 Allergan Plc. Company Information
13.5.2 Allergan Plc. Membranous Nephropathy Treatment Product Portfolios and Specifications
13.5.3 Allergan Plc. Membranous Nephropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Allergan Plc. Main Business Overview
13.5.5 Allergan Plc. Latest Developments
13.6 Amgen Inc
13.6.1 Amgen Inc Company Information
13.6.2 Amgen Inc Membranous Nephropathy Treatment Product Portfolios and Specifications
13.6.3 Amgen Inc Membranous Nephropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Amgen Inc Main Business Overview
13.6.5 Amgen Inc Latest Developments
13.7 Pfizer Inc.
13.7.1 Pfizer Inc. Company Information
13.7.2 Pfizer Inc. Membranous Nephropathy Treatment Product Portfolios and Specifications
13.7.3 Pfizer Inc. Membranous Nephropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Pfizer Inc. Main Business Overview
13.7.5 Pfizer Inc. Latest Developments
13.8 Novartis. AG.
13.8.1 Novartis. AG. Company Information
13.8.2 Novartis. AG. Membranous Nephropathy Treatment Product Portfolios and Specifications
13.8.3 Novartis. AG. Membranous Nephropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Novartis. AG. Main Business Overview
13.8.5 Novartis. AG. Latest Developments
13.9 Apotex Inc.
13.9.1 Apotex Inc. Company Information
13.9.2 Apotex Inc. Membranous Nephropathy Treatment Product Portfolios and Specifications
13.9.3 Apotex Inc. Membranous Nephropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Apotex Inc. Main Business Overview
13.9.5 Apotex Inc. Latest Developments
13.10 Teva Pharma Industries Ltd.
13.10.1 Teva Pharma Industries Ltd. Company Information
13.10.2 Teva Pharma Industries Ltd. Membranous Nephropathy Treatment Product Portfolios and Specifications
13.10.3 Teva Pharma Industries Ltd. Membranous Nephropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Teva Pharma Industries Ltd. Main Business Overview
13.10.5 Teva Pharma Industries Ltd. Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Membranous Nephropathy Treatment Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Membranous Nephropathy Treatment Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Alkylating Agents
Table 4. Major Players of Cyclophosphamide
Table 5. Major Players of Chlorambucil
Table 6. Major Players of Cyclic Peptides
Table 7. Major Players of Tacrolimus
Table 8. Major Players of MycophenolateMofetil
Table 9. Major Players of Others
Table 10. Global Membranous Nephropathy Treatment Sales by Type (2018-2023) & (K Units)
Table 11. Global Membranous Nephropathy Treatment Sales Market Share by Type (2018-2023)
Table 12. Global Membranous Nephropathy Treatment Revenue by Type (2018-2023) & ($ million)
Table 13. Global Membranous Nephropathy Treatment Revenue Market Share by Type (2018-2023)
Table 14. Global Membranous Nephropathy Treatment Sale Price by Type (2018-2023) & (US$/Unit)
Table 15. Global Membranous Nephropathy Treatment Sales by Application (2018-2023) & (K Units)
Table 16. Global Membranous Nephropathy Treatment Sales Market Share by Application (2018-2023)
Table 17. Global Membranous Nephropathy Treatment Revenue by Application (2018-2023)
Table 18. Global Membranous Nephropathy Treatment Revenue Market Share by Application (2018-2023)
Table 19. Global Membranous Nephropathy Treatment Sale Price by Application (2018-2023) & (US$/Unit)
Table 20. Global Membranous Nephropathy Treatment Sales by Company (2018-2023) & (K Units)
Table 21. Global Membranous Nephropathy Treatment Sales Market Share by Company (2018-2023)
Table 22. Global Membranous Nephropathy Treatment Revenue by Company (2018-2023) ($ Millions)
Table 23. Global Membranous Nephropathy Treatment Revenue Market Share by Company (2018-2023)
Table 24. Global Membranous Nephropathy Treatment Sale Price by Company (2018-2023) & (US$/Unit)
Table 25. Key Manufacturers Membranous Nephropathy Treatment Producing Area Distribution and Sales Area
Table 26. Players Membranous Nephropathy Treatment Products Offered
Table 27. Membranous Nephropathy Treatment Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 28. New Products and Potential Entrants
Table 29. Mergers & Acquisitions, Expansion
Table 30. Global Membranous Nephropathy Treatment Sales by Geographic Region (2018-2023) & (K Units)
Table 31. Global Membranous Nephropathy Treatment Sales Market Share Geographic Region (2018-2023)
Table 32. Global Membranous Nephropathy Treatment Revenue by Geographic Region (2018-2023) & ($ millions)
Table 33. Global Membranous Nephropathy Treatment Revenue Market Share by Geographic Region (2018-2023)
Table 34. Global Membranous Nephropathy Treatment Sales by Country/Region (2018-2023) & (K Units)
Table 35. Global Membranous Nephropathy Treatment Sales Market Share by Country/Region (2018-2023)
Table 36. Global Membranous Nephropathy Treatment Revenue by Country/Region (2018-2023) & ($ millions)
Table 37. Global Membranous Nephropathy Treatment Revenue Market Share by Country/Region (2018-2023)
Table 38. Americas Membranous Nephropathy Treatment Sales by Country (2018-2023) & (K Units)
Table 39. Americas Membranous Nephropathy Treatment Sales Market Share by Country (2018-2023)
Table 40. Americas Membranous Nephropathy Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 41. Americas Membranous Nephropathy Treatment Revenue Market Share by Country (2018-2023)
Table 42. Americas Membranous Nephropathy Treatment Sales by Type (2018-2023) & (K Units)
Table 43. Americas Membranous Nephropathy Treatment Sales by Application (2018-2023) & (K Units)
Table 44. APAC Membranous Nephropathy Treatment Sales by Region (2018-2023) & (K Units)
Table 45. APAC Membranous Nephropathy Treatment Sales Market Share by Region (2018-2023)
Table 46. APAC Membranous Nephropathy Treatment Revenue by Region (2018-2023) & ($ Millions)
Table 47. APAC Membranous Nephropathy Treatment Revenue Market Share by Region (2018-2023)
Table 48. APAC Membranous Nephropathy Treatment Sales by Type (2018-2023) & (K Units)
Table 49. APAC Membranous Nephropathy Treatment Sales by Application (2018-2023) & (K Units)
Table 50. Europe Membranous Nephropathy Treatment Sales by Country (2018-2023) & (K Units)
Table 51. Europe Membranous Nephropathy Treatment Sales Market Share by Country (2018-2023)
Table 52. Europe Membranous Nephropathy Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 53. Europe Membranous Nephropathy Treatment Revenue Market Share by Country (2018-2023)
Table 54. Europe Membranous Nephropathy Treatment Sales by Type (2018-2023) & (K Units)
Table 55. Europe Membranous Nephropathy Treatment Sales by Application (2018-2023) & (K Units)
Table 56. Middle East & Africa Membranous Nephropathy Treatment Sales by Country (2018-2023) & (K Units)
Table 57. Middle East & Africa Membranous Nephropathy Treatment Sales Market Share by Country (2018-2023)
Table 58. Middle East & Africa Membranous Nephropathy Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 59. Middle East & Africa Membranous Nephropathy Treatment Revenue Market Share by Country (2018-2023)
Table 60. Middle East & Africa Membranous Nephropathy Treatment Sales by Type (2018-2023) & (K Units)
Table 61. Middle East & Africa Membranous Nephropathy Treatment Sales by Application (2018-2023) & (K Units)
Table 62. Key Market Drivers & Growth Opportunities of Membranous Nephropathy Treatment
Table 63. Key Market Challenges & Risks of Membranous Nephropathy Treatment
Table 64. Key Industry Trends of Membranous Nephropathy Treatment
Table 65. Membranous Nephropathy Treatment Raw Material
Table 66. Key Suppliers of Raw Materials
Table 67. Membranous Nephropathy Treatment Distributors List
Table 68. Membranous Nephropathy Treatment Customer List
Table 69. Global Membranous Nephropathy Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 70. Global Membranous Nephropathy Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Americas Membranous Nephropathy Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Americas Membranous Nephropathy Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. APAC Membranous Nephropathy Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 74. APAC Membranous Nephropathy Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 75. Europe Membranous Nephropathy Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 76. Europe Membranous Nephropathy Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Middle East & Africa Membranous Nephropathy Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 78. Middle East & Africa Membranous Nephropathy Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 79. Global Membranous Nephropathy Treatment Sales Forecast by Type (2024-2029) & (K Units)
Table 80. Global Membranous Nephropathy Treatment Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 81. Global Membranous Nephropathy Treatment Sales Forecast by Application (2024-2029) & (K Units)
Table 82. Global Membranous Nephropathy Treatment Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 83. Abbie. Inc. Basic Information, Membranous Nephropathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 84. Abbie. Inc. Membranous Nephropathy Treatment Product Portfolios and Specifications
Table 85. Abbie. Inc. Membranous Nephropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Abbie. Inc. Main Business
Table 87. Abbie. Inc. Latest Developments
Table 88. Astrazeneca Plc. Basic Information, Membranous Nephropathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 89. Astrazeneca Plc. Membranous Nephropathy Treatment Product Portfolios and Specifications
Table 90. Astrazeneca Plc. Membranous Nephropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Astrazeneca Plc. Main Business
Table 92. Astrazeneca Plc. Latest Developments
Table 93. F. Hoffman- La Roche Ltd. Basic Information, Membranous Nephropathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 94. F. Hoffman- La Roche Ltd. Membranous Nephropathy Treatment Product Portfolios and Specifications
Table 95. F. Hoffman- La Roche Ltd. Membranous Nephropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. F. Hoffman- La Roche Ltd. Main Business
Table 97. F. Hoffman- La Roche Ltd. Latest Developments
Table 98. Fibrogen Basic Information, Membranous Nephropathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 99. Fibrogen Membranous Nephropathy Treatment Product Portfolios and Specifications
Table 100. Fibrogen Membranous Nephropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Fibrogen Main Business
Table 102. Fibrogen Latest Developments
Table 103. Allergan Plc. Basic Information, Membranous Nephropathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 104. Allergan Plc. Membranous Nephropathy Treatment Product Portfolios and Specifications
Table 105. Allergan Plc. Membranous Nephropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Allergan Plc. Main Business
Table 107. Allergan Plc. Latest Developments
Table 108. Amgen Inc Basic Information, Membranous Nephropathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 109. Amgen Inc Membranous Nephropathy Treatment Product Portfolios and Specifications
Table 110. Amgen Inc Membranous Nephropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Amgen Inc Main Business
Table 112. Amgen Inc Latest Developments
Table 113. Pfizer Inc. Basic Information, Membranous Nephropathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 114. Pfizer Inc. Membranous Nephropathy Treatment Product Portfolios and Specifications
Table 115. Pfizer Inc. Membranous Nephropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Pfizer Inc. Main Business
Table 117. Pfizer Inc. Latest Developments
Table 118. Novartis. AG. Basic Information, Membranous Nephropathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 119. Novartis. AG. Membranous Nephropathy Treatment Product Portfolios and Specifications
Table 120. Novartis. AG. Membranous Nephropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. Novartis. AG. Main Business
Table 122. Novartis. AG. Latest Developments
Table 123. Apotex Inc. Basic Information, Membranous Nephropathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 124. Apotex Inc. Membranous Nephropathy Treatment Product Portfolios and Specifications
Table 125. Apotex Inc. Membranous Nephropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. Apotex Inc. Main Business
Table 127. Apotex Inc. Latest Developments
Table 128. Teva Pharma Industries Ltd. Basic Information, Membranous Nephropathy Treatment Manufacturing Base, Sales Area and Its Competitors
Table 129. Teva Pharma Industries Ltd. Membranous Nephropathy Treatment Product Portfolios and Specifications
Table 130. Teva Pharma Industries Ltd. Membranous Nephropathy Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 131. Teva Pharma Industries Ltd. Main Business
Table 132. Teva Pharma Industries Ltd. Latest Developments
List of Figures
Figure 1. Picture of Membranous Nephropathy Treatment
Figure 2. Membranous Nephropathy Treatment Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Membranous Nephropathy Treatment Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Membranous Nephropathy Treatment Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Membranous Nephropathy Treatment Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Alkylating Agents
Figure 10. Product Picture of Cyclophosphamide
Figure 11. Product Picture of Chlorambucil
Figure 12. Product Picture of Cyclic Peptides
Figure 13. Product Picture of Tacrolimus
Figure 14. Product Picture of MycophenolateMofetil
Figure 15. Product Picture of Others
Figure 16. Global Membranous Nephropathy Treatment Sales Market Share by Type in 2022
Figure 17. Global Membranous Nephropathy Treatment Revenue Market Share by Type (2018-2023)
Figure 18. Membranous Nephropathy Treatment Consumed in Hospital pharmacy
Figure 19. Global Membranous Nephropathy Treatment Market: Hospital pharmacy (2018-2023) & (K Units)
Figure 20. Membranous Nephropathy Treatment Consumed in Retail pharmacy
Figure 21. Global Membranous Nephropathy Treatment Market: Retail pharmacy (2018-2023) & (K Units)
Figure 22. Membranous Nephropathy Treatment Consumed in Online Pharmacy
Figure 23. Global Membranous Nephropathy Treatment Market: Online Pharmacy (2018-2023) & (K Units)
Figure 24. Global Membranous Nephropathy Treatment Sales Market Share by Application (2022)
Figure 25. Global Membranous Nephropathy Treatment Revenue Market Share by Application in 2022
Figure 26. Membranous Nephropathy Treatment Sales Market by Company in 2022 (K Units)
Figure 27. Global Membranous Nephropathy Treatment Sales Market Share by Company in 2022
Figure 28. Membranous Nephropathy Treatment Revenue Market by Company in 2022 ($ Million)
Figure 29. Global Membranous Nephropathy Treatment Revenue Market Share by Company in 2022
Figure 30. Global Membranous Nephropathy Treatment Sales Market Share by Geographic Region (2018-2023)
Figure 31. Global Membranous Nephropathy Treatment Revenue Market Share by Geographic Region in 2022
Figure 32. Americas Membranous Nephropathy Treatment Sales 2018-2023 (K Units)
Figure 33. Americas Membranous Nephropathy Treatment Revenue 2018-2023 ($ Millions)
Figure 34. APAC Membranous Nephropathy Treatment Sales 2018-2023 (K Units)
Figure 35. APAC Membranous Nephropathy Treatment Revenue 2018-2023 ($ Millions)
Figure 36. Europe Membranous Nephropathy Treatment Sales 2018-2023 (K Units)
Figure 37. Europe Membranous Nephropathy Treatment Revenue 2018-2023 ($ Millions)
Figure 38. Middle East & Africa Membranous Nephropathy Treatment Sales 2018-2023 (K Units)
Figure 39. Middle East & Africa Membranous Nephropathy Treatment Revenue 2018-2023 ($ Millions)
Figure 40. Americas Membranous Nephropathy Treatment Sales Market Share by Country in 2022
Figure 41. Americas Membranous Nephropathy Treatment Revenue Market Share by Country in 2022
Figure 42. Americas Membranous Nephropathy Treatment Sales Market Share by Type (2018-2023)
Figure 43. Americas Membranous Nephropathy Treatment Sales Market Share by Application (2018-2023)
Figure 44. United States Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 45. Canada Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 46. Mexico Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 47. Brazil Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 48. APAC Membranous Nephropathy Treatment Sales Market Share by Region in 2022
Figure 49. APAC Membranous Nephropathy Treatment Revenue Market Share by Regions in 2022
Figure 50. APAC Membranous Nephropathy Treatment Sales Market Share by Type (2018-2023)
Figure 51. APAC Membranous Nephropathy Treatment Sales Market Share by Application (2018-2023)
Figure 52. China Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 53. Japan Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 54. South Korea Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 55. Southeast Asia Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 56. India Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 57. Australia Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 58. China Taiwan Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 59. Europe Membranous Nephropathy Treatment Sales Market Share by Country in 2022
Figure 60. Europe Membranous Nephropathy Treatment Revenue Market Share by Country in 2022
Figure 61. Europe Membranous Nephropathy Treatment Sales Market Share by Type (2018-2023)
Figure 62. Europe Membranous Nephropathy Treatment Sales Market Share by Application (2018-2023)
Figure 63. Germany Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 64. France Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 65. UK Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 66. Italy Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 67. Russia Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 68. Middle East & Africa Membranous Nephropathy Treatment Sales Market Share by Country in 2022
Figure 69. Middle East & Africa Membranous Nephropathy Treatment Revenue Market Share by Country in 2022
Figure 70. Middle East & Africa Membranous Nephropathy Treatment Sales Market Share by Type (2018-2023)
Figure 71. Middle East & Africa Membranous Nephropathy Treatment Sales Market Share by Application (2018-2023)
Figure 72. Egypt Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 73. South Africa Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 74. Israel Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 75. Turkey Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 76. GCC Country Membranous Nephropathy Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 77. Manufacturing Cost Structure Analysis of Membranous Nephropathy Treatment in 2022
Figure 78. Manufacturing Process Analysis of Membranous Nephropathy Treatment
Figure 79. Industry Chain Structure of Membranous Nephropathy Treatment
Figure 80. Channels of Distribution
Figure 81. Global Membranous Nephropathy Treatment Sales Market Forecast by Region (2024-2029)
Figure 82. Global Membranous Nephropathy Treatment Revenue Market Share Forecast by Region (2024-2029)
Figure 83. Global Membranous Nephropathy Treatment Sales Market Share Forecast by Type (2024-2029)
Figure 84. Global Membranous Nephropathy Treatment Revenue Market Share Forecast by Type (2024-2029)
Figure 85. Global Membranous Nephropathy Treatment Sales Market Share Forecast by Application (2024-2029)
Figure 86. Global Membranous Nephropathy Treatment Revenue Market Share Forecast by Application (2024-2029)


★調査レポート[世界の膜性腎症治療市場予測 2023年-2029年] (コード：LP23DC11025)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の膜性腎症治療市場予測 2023年-2029年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のIgA腎症治療市場予測2023-2029：副腎皮質ステロイド、免疫抑制剤、ACE・ARB阻害剤
  • 世界のIgA腎症治療薬市場予測2023-2029：第I相、第II相、第III相
  • 世界の筋骨格系腫瘍治療市場予測 2023年-2029年
  • 世界の前立腺肥大症治療装置市場予測 2023年-2029年
  • 世界のアルコール使用障害用治療市場予測 2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆